Aura BiosciencesAURA
Market Cap: $486M
About: Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Employees: 89
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
84% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 19
2.86% more ownership
Funds ownership: 79.68% [Q1] → 82.54% (+2.86%) [Q2]
0% more capital invested
Capital invested by funds: $308M [Q1] → $309M (+$1.38M) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
5% less funds holding
Funds holding: 78 [Q1] → 74 (-4) [Q2]
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
57% less call options, than puts
Call options by funds: $6K | Put options by funds: $14K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
JMP Securities Jonathan Wolleben 47% 1-year accuracy 28 / 59 met price target | 94%upside $19 | Market Outperform Reiterated | 28 Aug 2024 |
HC Wainwright & Co. Edward White 30% 1-year accuracy 31 / 104 met price target | 114%upside $21 | Buy Initiated | 25 Jul 2024 |
Financial journalist opinion
Based on 5 articles about AURA published over the past 30 days